Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.
Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP, Hoyles RK, Parfrey H, Renzoni EA, Kokosi M, Wells AU, Ashby D, Szigeti M, Molyneaux PL; RECITAL Investigators. Maher TM, et al. Among authors: fletcher sv. Lancet Respir Med. 2023 Jan;11(1):45-54. doi: 10.1016/S2213-2600(22)00359-9. Epub 2022 Nov 11. Lancet Respir Med. 2023. PMID: 36375479 Free article. Clinical Trial.
Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice.
Fletcher SV, Jones MG, Renzoni EA, Parfrey H, Hoyles RK, Spinks K, Kokosi M, Kwok A, Warburton C, Titmuss V, Thillai M, Simler N, Maher TM, Brereton CJ, Chua F, Wells AU, Richeldi L, Spencer LG. Fletcher SV, et al. ERJ Open Res. 2018 Oct 19;4(4):00049-2018. doi: 10.1183/23120541.00049-2018. eCollection 2018 Oct. ERJ Open Res. 2018. PMID: 30364342 Free PMC article.
The burden of progressive fibrotic interstitial lung disease across the UK.
Simpson T, Barratt SL, Beirne P, Chaudhuri N, Crawshaw A, Crowley LE, Fletcher S, Gibbons MA, Hallchurch P, Horgan L, Jakaityte I, Lewis T, McLellan T, Myall KJ, Miller R, Smith DJF, Stanel S, Thillai M, Thompson F, Wallis T, Wu Z, Molyneaux PL, West AG. Simpson T, et al. Eur Respir J. 2021 Jul 8;58(1):2100221. doi: 10.1183/13993003.00221-2021. Print 2021 Jul. Eur Respir J. 2021. PMID: 33678609 Free PMC article.
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, Dellaripa PF, Gooptu B, Vassallo R, Cox PG, Flaherty KR, Adamali HI, Gibbons MA, Troy L, Forrest IA, Lasky JA, Spencer LG, Golden J, Scholand MB, Chaudhuri N, Perrella MA, Lynch DA, Chambers DC, Kolb M, Spino C, Raghu G, Goldberg HJ, Rosas IO; TRAIL1 Network Investigators. Solomon JJ, et al. Lancet Respir Med. 2023 Jan;11(1):87-96. doi: 10.1016/S2213-2600(22)00260-0. Epub 2022 Sep 5. Lancet Respir Med. 2023. PMID: 36075242 Clinical Trial.
A hyperinflammation clinical risk tool, HI5-NEWS2, stratifies hospitalised COVID-19 patients to associate risk of death and effect of early dexamethasone in an observational cohort.
Ardern-Jones MR, Phan HTT, Borca F, Stammers M, Batchelor J, Reading IC, Fletcher SV, Smith T, Duncombe AS. Ardern-Jones MR, et al. Among authors: fletcher sv. PLoS One. 2023 Jan 17;18(1):e0280079. doi: 10.1371/journal.pone.0280079. eCollection 2023. PLoS One. 2023. PMID: 36649371 Free PMC article.
The safety of new drug treatments for idiopathic pulmonary fibrosis.
Fletcher S, Jones MG, Spinks K, Sgalla G, Marshall BG, Limbrey R, Richeldi L. Fletcher S, et al. Expert Opin Drug Saf. 2016 Nov;15(11):1483-1489. doi: 10.1080/14740338.2016.1218470. Epub 2016 Aug 17. Expert Opin Drug Saf. 2016. PMID: 27532218 Review.
Temporal progression of mediastinal lymphadenopathy in idiopathic pulmonary fibrosis.
Wallis TJM, Gudmundsson E, Pontoppidan K, Mogulkoc N, Savaş R, Unat ÖS, Vedwan K, Battison S, Thompson FJ, Brereton CJ, Marshall BG, Fletcher SV, Richeldi L, Jacob J, Jones MG. Wallis TJM, et al. Among authors: fletcher sv. Eur Respir J. 2022 Apr 21;59(4):2200024. doi: 10.1183/13993003.00024-2022. Print 2022 Apr. Eur Respir J. 2022. PMID: 35115340 Free PMC article. No abstract available.
25 results